A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis

Inclusion Criteria

• •Inclusion:
• •1. Symptomatic OA of hip (K-L Grade 1-3) documented by x-ray taken within the past 6 months
• •2. Male or female age 30 - 65 at time of enrollment
• •3. Patients must have adequate immune system function with no known immunodeficiency
• •4. disease
• •5. Has not had a corticosteroid injection in the past 6 months
• •6. Has not used non-steroidal anti-inflammatory 7 days prior to treatment and has not used oral
• •7. corticosteroids 30 days prior to treatment
• •8. If on chronic anticoagulant medication, we will follow the recommendations of the physician
• •9. managing their anticoagulant medication
• •10. Willing and able to participate for the entire study period
• •11. No evidence of current systemic infection or illness (eg. fever, malaise, etc.) and no evidence
• •12. of skin infection in the areas where the injection will be performed
• •Exclusion:
• •1. Patients have been diagnosed with an autoimmune disease, diabetes, rheumatoid arthritis,
• •2. hematologic conditions predisposing to bleeding disorders or platelet dysfunction, Paget's disease of femur or ilium, avascular necrosis (AVN) of the femoral head, infectious arthritis, Lyme disease.
• •3. Previous reparative cellular/ orthobiologics /PRP injection
• •4. ≥7mm hip effusion as measured on ultrasound at the femoral neck
• •5. K-L Grade 4 OA x-ray documented
• •6. Patient has a history of alcohol or drug abuse within the six months prior to enrolment in the study
• •7. Patients who had intra-articular treatment with corticosteroids within 6 months of randomization in this study
• •8. Patient received more than 2 previous intra- or extra-articular corticosteroid injections to the affected hip.
• •9. Patients who are pregnant or nursing at the time of consent
• •10. Patients who have had anorexia, chronic insomnia, immunocompromised state, and/ or are on immunosuppressive medication
• •11. Neoplastic cancer within 5 years prior to screening and no evidence of recurrence, except for cutaneous (basal cell and squamous cell) cancer treated with excision
• •12. History of chemotherapy within the past 3 years or radiation therapy to the involved hip area
• •13. Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)
• •14. Patients who have had previous intervention to the hip except for labral repair/ reconstruction and/ or femoral neck osteoplasty or acetabular osteoplasty without microfracture.
• •15. Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.
• •16. Use of NSAID 7 days prior to treatment or oral or subcutaneous corticosteroids 30 days prior
• •17. Patients with a BMI over 35
• •18. Deformity or dysplasia (i.e. Legg Calve Perthes or DDH) other than FAI.
• •19. Patients with systemic infection, hematological conditions, malignancy, blood borne diseases, allergies to lidocaine.